CorMedix Inc at JMP Securities Life Sciences Conference Transcript
Thanks again. Good morning, everybody. I appreciate you being with us this morning at the JMP Securities Life Science Conference. Excited to have CorMedix join us next. And with us is CEO, Joe Todisco. Joe, thank you for being with us. Super exciting day with the announcement of the DefenCath NDA submission. So I'm sure we will get to that in a minute.
Questions & Answers
But before we do that, I just wanted to start off. You've been CEO now for a little over a year. Can you just give us a quick overview of the company, DefenCath, and to what originally drew you to the opportunity?
Sure. Look, I think I'm a year and three days to be exact. CorMedix is essentially a pre-commercial stage biotech. Our lead product, DefenCath is a catheter lock solution, with the initial indication focused on preventing catheter-related bloodstream infections in hemodialysis patients that have a central venous
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |